<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent USRE40812 - Liquid pharmaceutical composition for nasal administration comprising ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_4ff636b3d23669b7103f3b3a3a18b4cd/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_4ff636b3d23669b7103f3b3a3a18b4cd__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Liquid pharmaceutical composition for nasal administration comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from citric acid, citric acid salt, and combination thereof, wherein combined concentration of all bioavailability enhancing agents is 10-25 mM"><meta name="DC.contributor" content="William Stern" scheme="inventor"><meta name="DC.contributor" content="Unigene Laboratories Inc." scheme="assignee"><meta name="DC.date" content="2004-2-5" scheme="dateSubmitted"><meta name="DC.description" content="A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration.A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof."><meta name="DC.date" content="2009-6-30" scheme="issued"><meta name="DC.relation" content="EP:0115627:A1" scheme="references"><meta name="DC.relation" content="EP:0327756:A2" scheme="references"><meta name="DC.relation" content="EP:0358234:A2" scheme="references"><meta name="DC.relation" content="EP:0371010:A1" scheme="references"><meta name="DC.relation" content="EP:0418697:A1" scheme="references"><meta name="DC.relation" content="EP:0489217:A1" scheme="references"><meta name="DC.relation" content="EP:0726075:A1" scheme="references"><meta name="DC.relation" content="EP:0809512:A1" scheme="references"><meta name="DC.relation" content="GB:2092002" scheme="references"><meta name="DC.relation" content="JP:H0578258" scheme="references"><meta name="DC.relation" content="US:4151276" scheme="references"><meta name="DC.relation" content="US:4690952" scheme="references"><meta name="DC.relation" content="US:4788221" scheme="references"><meta name="DC.relation" content="US:4845080" scheme="references"><meta name="DC.relation" content="US:4900730" scheme="references"><meta name="DC.relation" content="US:5023252" scheme="references"><meta name="DC.relation" content="US:5026825" scheme="references"><meta name="DC.relation" content="US:5059587" scheme="references"><meta name="DC.relation" content="US:5124315" scheme="references"><meta name="DC.relation" content="US:5183802" scheme="references"><meta name="DC.relation" content="US:5234906" scheme="references"><meta name="DC.relation" content="US:5279836" scheme="references"><meta name="DC.relation" content="US:5281580" scheme="references"><meta name="DC.relation" content="US:5310727" scheme="references"><meta name="DC.relation" content="US:5496801" scheme="references"><meta name="DC.relation" content="US:5514365" scheme="references"><meta name="DC.relation" content="US:5534496" scheme="references"><meta name="DC.relation" content="US:5536508" scheme="references"><meta name="DC.relation" content="US:5571788" scheme="references"><meta name="DC.relation" content="US:5593962" scheme="references"><meta name="DC.relation" content="US:5637309" scheme="references"><meta name="DC.relation" content="US:5654000" scheme="references"><meta name="DC.relation" content="US:5665700" scheme="references"><meta name="DC.relation" content="US:5693608" scheme="references"><meta name="DC.relation" content="US:5700486" scheme="references"><meta name="DC.relation" content="US:5714477" scheme="references"><meta name="DC.relation" content="US:5719122" scheme="references"><meta name="DC.relation" content="US:5725871" scheme="references"><meta name="DC.relation" content="US:5726154" scheme="references"><meta name="DC.relation" content="US:5733569" scheme="references"><meta name="DC.relation" content="US:5733572" scheme="references"><meta name="DC.relation" content="US:5759565" scheme="references"><meta name="DC.relation" content="US:5759566" scheme="references"><meta name="DC.relation" content="US:5776886" scheme="references"><meta name="DC.relation" content="US:5858391" scheme="references"><meta name="DC.relation" content="US:5912014" scheme="references"><meta name="DC.relation" content="US:5938654" scheme="references"><meta name="DC.relation" content="US:5968899" scheme="references"><meta name="DC.relation" content="US:6008189" scheme="references"><meta name="DC.relation" content="US:6017538" scheme="references"><meta name="DC.relation" content="US:6086918" scheme="references"><meta name="DC.relation" content="US:6087338" scheme="references"><meta name="DC.relation" content="US:6107277" scheme="references"><meta name="DC.relation" content="US:6149893" scheme="references"><meta name="DC.relation" content="US:6153582" scheme="references"><meta name="DC.relation" content="US:6348207" scheme="references"><meta name="DC.relation" content="US:6440392" scheme="references"><meta name="DC.relation" content="US:6440446" scheme="references"><meta name="DC.relation" content="US:6447785" scheme="references"><meta name="DC.relation" content="US:6509006" scheme="references"><meta name="citation_reference" content="A.E. Pontiroli, et al., Intranasal calcitonin and plasma calcium concentrations in normal subjects, British Medical Journal, Clinical Research ed., 290:1390-1391. (1985)."><meta name="citation_reference" content="Abe K., et al., Chem. Pharm. Bull (Tokyo) Dec. 1995; 43 (12): 2232-7, &quot;Enhanced Nasal Delivery of Luteinizing Hormone Releasing Agonist Buserelin by Oleic Acid Solubilized and Stabilized in Hydroxypropyl-beta-cyclodextrin&quot;, abstract."><meta name="citation_reference" content="Agerholm C., et al., J. Pharm. Sci. Dec. 1994; 83 (12) : 1706-11, &quot;Epithelial Transport and Bioavailability of Intranasally Administered Human Growth Hormone Formulated with the Absorption Enhancers Didecanoyl-L-alpha-phosphatidylcholine and alpha-cyclodextrin in Rabbits&quot;, abstract."><meta name="citation_reference" content="Akers and DeFelippis, Pharmaceutical Formulation Development of Peptides and Proteins, (published 2000), Sven Frokjaer and Lars Hovgaard, Editors Pharmaceutical Formulation Development of Peptides and Proteins, pp. 145-177, CRC Press 2000."><meta name="citation_reference" content="Akwete Lex Adjei and Pramod K. Gupta, Editors, Inhalation Delivery of Therapeutic Peptides and Proteins, 1997:493-514, Marcel Dekker, Inc."><meta name="citation_reference" content="Amended Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims, Unigene Laboratories, Inc. et at. v. Apotex, Inc., et al., Civil Action No. 06-CV-5571-RPP-THK EFC Case (S.D.N.Y.), May 8, 2007."><meta name="citation_reference" content="Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims, Unigene Laboratories Inc., et al. v. Apotex Inc., et al., Civil Action No. 06-CV-5571-RPP-THK, EFC Case (S.D.N.Y.) Sep. 20, 2006."><meta name="citation_reference" content="Apotex Notice Letter-Jun. 1, 2006."><meta name="citation_reference" content="Armyn P. Sayani, et al. &quot;Systemic Delivery of Peptides and Proteins Across Absorptive Mucoase&quot;, Critical Reviews in Therapeutic Drug Carrier Systems, 13 (1&amp;2):85-184 at pp. 106,127,128,144,158,160 (1996)."><meta name="citation_reference" content="Bell, L.N., &quot;Peptide stability in solids and solutions&quot;, Biotechnology Progress 13:342-346. (1997)."><meta name="citation_reference" content="Berg et al., Laryngoscope 104:1153-1158; 1994 &quot;The Effect of Decongestive Nosedrops on Human Respiratory Mucosa In Vitro&quot;."><meta name="citation_reference" content="Biotechnology Newswatch, vol. 9, No. 12; p. 1, &quot;Two-nasally delivered CalBio hormones pass initial clinicals&quot;, Jun. 19, 1989."><meta name="citation_reference" content="Caspar W.R., et al. , Drug &amp; Cosmetic Industry, vol. 156; No. 1; p. 46, &quot;New Ways of Enhancing the Delivery of Skin Care Ingredients&quot;, Jan. 1995."><meta name="citation_reference" content="Complaint by Unigene Laboratories, Inc. et at. v. Apotex, Inc., et al., 06-cv-5571-RPP-THK (EFC Case)-U.S. District Court for the Southern District of New York."><meta name="citation_reference" content="Critchley H., et al., J. Pharm Pharmacol Aug. 1994; 46 (8) : 651-6, &quot;Nasal Absorption of Desmpressin in Rats and Sheep. Effect of A Bioadhesive Microsphere Delivery System&quot;, abstract."><meta name="citation_reference" content="D. Harris, et al., &quot;Bioadhesive polymers in peptide drug delivery&quot;, Biomaterials, 11:652-658. (1990)."><meta name="citation_reference" content="D. Voet and J.G. Voet, Biochemistry, 2nd Edition, John Wiley &amp; Sons, New York, pp. 538-541 (1995)."><meta name="citation_reference" content="Database WPI, Section Ch, Week 199317, Derwent Publications Ltd., London, GB; Class B04, AN 1993-140304, XP002300282 &amp; JP 05 078258 A (Suntory) Mar. 30, 1993."><meta name="citation_reference" content="Declaration of Ashim K. Mitra, Ph.D. Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK."><meta name="citation_reference" content="Declaration of Michael Sofocleous dated Oct. 13, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK."><meta name="citation_reference" content="Declaration of Professor Alexander M. Klibanov Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK."><meta name="citation_reference" content="Declaration of Professor Robert S. Langer Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK."><meta name="citation_reference" content="Donovan M.D., et al., Pharm. Res. Aug. 1990; 7 (8) : 808-15, &quot;The Molecular Weight Dependence of Nasal Absorption: the Effect of Absorption Enhancers&quot;, abstract."><meta name="citation_reference" content="Dua et al., International Journal of Pharmaceutics 147, 1997, pp. 233-242 &quot;The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits.&quot;"><meta name="citation_reference" content="European Search Report dated Oct. 10, 2004."><meta name="citation_reference" content="Expert Report of Dr. Robert P. Raymond, Esq., dated Dec. 2, 2008, pp. 1-23."><meta name="citation_reference" content="Expert Report of Henry Kwan, Ph.D. Regarding Validity of U.S. Pat. No. 6,440,392, dated Dec. 2, 2008, pp. 1-182."><meta name="citation_reference" content="Feb. 20, 2008 Defendants&#39; Notice of Motion in Support of Defendants&#39; Motion For Reconsideration of the Feb. 4, 2008 Order Regarding Defendants&#39; Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP)."><meta name="citation_reference" content="Feb. 20, 2008 Memorandum of Law in Support of Defendants&#39; Motion for Reconsideration of the of the Feb. 4, 2008 Order Regarding Defendants&#39; Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP)."><meta name="citation_reference" content="Feb. 28, 2008 Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP)."><meta name="citation_reference" content="Feb. 4, 2008 Opinion and Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP)."><meta name="citation_reference" content="H. Hallen et al., Clin. Exp. Allergy, vol. 25:401-405; 1995 &quot;Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers&quot;."><meta name="citation_reference" content="Hayashi, et al., &quot;Physiological mechanism for enhancement of paracellular drug transport&quot;, Journal of Controlled Release, 62: 141-148. (1999)."><meta name="citation_reference" content="Hosoya K., et al., Biol Pharm Bull Feb. 1994; 17 (2) : 316-22, &quot;Evaluation of Enhancers to Increase Nasal Absorption Using Ussing Chamber Technique&quot;, abstract."><meta name="citation_reference" content="Jacobs M.A., et al., Diabetes Nov. 1993; 41 (11) : 1649-55, &quot;The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers&quot;, abstract."><meta name="citation_reference" content="Jul. 14, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP)."><meta name="citation_reference" content="Jul. 15, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP)."><meta name="citation_reference" content="Jul. 16, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP)."><meta name="citation_reference" content="Kagatani S., et al., Pharm. Res. 1996 13/5 (739-743), &quot;Enhancement of Nasal Salmon Calcitonin Absorption by Lauroyclarnitine Chloride in Rats&quot;, abstract."><meta name="citation_reference" content="Kobayashi, S., et al., &quot;Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats&quot;, Pharmaceutical Research, 13:80-83. (1996)."><meta name="citation_reference" content="Kurosaki Y., et al., J. Pharmacobiodyn Dec. 1988; 11 (12) : 824-32, &quot;Application of Propranolol to the Keratinized Oral Mucosa: Avoidance of First-Pass Elimination and the Use of 1-Dodecylazacycloheptan-2-one (Azone) as an Absorption Enhancer of Bioadhesive Film-Dosage Form&quot;, abstract."><meta name="citation_reference" content="Lee, K.C. et al., &quot;Degradation of synthetic salmon calcitonin in aqueous solutions&quot;, Pharm. Res. 9:1521-1523. (1992)."><meta name="citation_reference" content="Li, Y., et al., &quot;Effect of a conjugated bile salt on the pulmonary absorption of insulin in rats&quot;, Eur. J. Pharm. Biopharm, 39:216-21. (1993)."><meta name="citation_reference" content="M. Gibson, Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commerical Dosage Form, p. 479 and Chapter 13, Aqueous Nasal Dosage Forms, Ed., Taylor &amp; Francis. (2001)."><meta name="citation_reference" content="M. Weiner and I. Leonard Bernstein, 1989, Adverse Reactions to Drug Formulation Agents, A Handbook of Excipients, Marcel Dekker, Inc. 1989, pp. 361-363 and 390-391."><meta name="citation_reference" content="M.J. Cho., et al., &quot;Citric acid as an adjuvant for transepithelial transport&quot; International Journal of Pharmaceutics, 52:79-81. (1989)."><meta name="citation_reference" content="Martin E., et al., Pharm Res May 1997; 14(5) : 631-7, &quot;Confocal laser scanning microscopic visualization of the transport of Dextrans after Nasal Administration to Rats: Effects of Absorption Enhancers&quot;, abstract."><meta name="citation_reference" content="Marttin E., Pharm. Res., May 1997, 14 (5): 631-7, &quot;Confocal Laser Scanning Microscopic Visualization of the Transport of Dextrans After Nasal Administration to Rats: Effects of Absorption Enhancers&quot;, abstract."><meta name="citation_reference" content="Morimoto K., et al., J. Pharma. Pharmacol. 1985 37/2 (134-136) &quot;Enhancement of Nasal Absorption of Insulin and Calcitonin Using Polyacrylic Acid Gel&quot;, abstract."><meta name="citation_reference" content="Morimoto K., et al., Pharm Res Sep. 1991; 8 (9) : 1175-9, &quot;Effects of Proteolytic Enzyme Inhibitors on the Nasal Absorption of Vasoppressin and an Analogue&quot;, abstract."><meta name="citation_reference" content="N.R. Anderson, et al., &quot;Quantitative evaluation of pharmaceutical effervescent systems II: Stability monitoring by reactivity and porosity measurements&quot;, Journal of Pharmaceutical Sciences, 71:7-13. (1982)."><meta name="citation_reference" content="Nov. 6, 2007 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP)."><meta name="citation_reference" content="Observations on European Patent Application No. EP 1251867 (third party observations) dated Jan. 17, 2003."><meta name="citation_reference" content="Office Action from the European Patent Office concerning European Application Serial No. 01 908 769.1-1219 dated Feb. 2, 2007."><meta name="citation_reference" content="Okamoto H., et al., J. Pharm. Pharmacol Jul. 1987; 39 (7) : 531-4, &quot;Enhanced penetration of mitromycin C through hairless mouse and rats skin by enhancers with terpene moieties&quot;, abstract."><meta name="citation_reference" content="Opinion and Order dated Aug. 28, 2008, in Unigene Laboratories, Inc., et al. v. Apotex, Inc., et al., 06, CV 5571 (RPP)."><meta name="citation_reference" content="P. Graf et al., Clin., Exp. Allergy, vol. 25:395-400; 1995 &quot;Benzalkoium chloride in a decongestant nasal spray aggravates Rhinitis medicamentosa in healthy volunteers&quot;."><meta name="citation_reference" content="P. Nykänen, et al., &quot;Organic acids as excipients in matrix granules for colon-specific drug delivery&quot;, Int. J. Pharm. 184:251-261. (1999)."><meta name="citation_reference" content="P.C. Braga et al., J. Pharm. Pharmacol. 44:938-940; 1992 &quot;The effects of calcitonin nsala preparations and their excipients on mucociliary clearance in an ex-vivo frog palate test&quot;."><meta name="citation_reference" content="Patent family search for EP 0358234 (equiv. USP 5,026,825),1/34/1 Dialog(R) File 351:Derwent abstract, (008189979, &quot;Intranasal calcitonin formulations-contg. Delta-amino-laevulinic acid for enhanced bioavailability&quot; (priority application 1988)."><meta name="citation_reference" content="Patent family search for GB 2212062 (equiv. EP 0327756), 2/34/1 Dialog(R) File 351: Derwent abstract, 007943804, &quot;Pharmaceutical Calcitonin-contg. for nasal glycyrrihizinate to enhance mucosal membrane absorption, esp. for nasal administration&quot; (priority application 1987)."><meta name="citation_reference" content="Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippincott Williams &amp; Wilkins, pp. 77-81 (1999)."><meta name="citation_reference" content="Physicians&#39; Desk Reference 52nd Edition at 1880-1881 (1998)."><meta name="citation_reference" content="Physicians&#39; Desk Reference-PDR 53 Edition 1999, pp. 2057-2059."><meta name="citation_reference" content="Pillion D.J., et al., J. Pharm. Sci. Nov. 1995; 84 (11) : 1276-9, &quot;DS-1, A Modified Quillaja Saponin, Enhances Ocula and Nasal Absorption of Insulin&quot;, abstract."><meta name="citation_reference" content="Plaintiffs&#39; Memorandum of Law in Opposition to Defendants&#39; Motion for Reconsideration of the Feb. 4, 2008 Order Regarding Defendants&#39; Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP)."><meta name="citation_reference" content="Pontiroli A.E., et al., Eur J Clin Pharmacol 1989; 37 (4) : 427-30, &quot;Nasal Administration of Glucagon and Human Calcitonin to Healthy Subjects: A Comparison of Powders and Spray Solutions and of Different Enhancing Agents&quot;, abstract."><meta name="citation_reference" content="R.C. Henrikson, et al., Histology, Lippincott Williams and Wilkins pp. 311-321 at 314 (1997)."><meta name="citation_reference" content="Ratafia, Manny, et al. M&amp;M Medical Marketing &amp; Media, vol. 24; No. 11, p. 10; &quot;Drug Delivery: the Key to Biotechnology Markets&quot;, Oct. 1, 1989."><meta name="citation_reference" content="Rebuttal Declaration and Expert Report of Ashim K. Mitra, Ph.D."><meta name="citation_reference" content="Rebuttal Declaration and Expert Report of Michael Sofocleous."><meta name="citation_reference" content="Rebuttal Declaration and Expert Report of Professor Alexander M. Klibanov Regarding Invalidity of U.S. Pat. No. 6,440,392."><meta name="citation_reference" content="Rebuttal Declaration and Expert Report of Professor Robert S. Langer Regarding Invalidity of U.S. Pat. No. 6,440,392."><meta name="citation_reference" content="Remington, The Science and Practice of Pharmacy, 20th Edition, Philadelphia (USA) Jan. 2000, Chapter 47, pp. 922-923."><meta name="citation_reference" content="Repertorio Farmaceutico Italiano, REFI 4a Edizione (REFI 4th Edition), 1990, p. A 212, (Calcitonina Spray Nasale Arnmour, and p. A223 &quot;Carbicalcin Spray&quot;, Farmindustria, Associazione dell&#39;Idustria Farmaceutica (National Association of the Pharmaceutical Industry)-CEDOF Editor, 1990."><meta name="citation_reference" content="Reubsaet et al., &quot;Degradation kinetics of antagonist [Arg6, D-Trp7,9, MePhe8]-substance P{6-11} in aqueous solutions&quot;, Analytical Biochemistry 227:334-341. (1995)."><meta name="citation_reference" content="Romeijn S.G., et al., Int. J. Pharm.,1996,135/1-2 (137-145), &quot;The Effect of Nasal Drug Formulations on Ciliary Beating in vitro&quot;, abstract."><meta name="citation_reference" content="Santus G., et al., Farmaco Dec. 1993; 48 (12) : 1709-33, &quot;Nasal Formulations of Ketorolac Tromethamine: Technological Evaluation-Bioavailability and Tolerability in Rabbits&quot;, abstract."><meta name="citation_reference" content="Sarkar M.A., Pharm Res Jan. 1992; 9 (1) : 1-9, &quot;Drug Metabolism in the Nasal Mucosa&quot;, abstract."><meta name="citation_reference" content="Schipper N.G., et al., Pharm Res Nov. 1996; 13 (11) : 1686-92, &quot;Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells&quot;, abstract."><meta name="citation_reference" content="Schipper N.G.M., et al., Calcif. Tissue Int.,1995, 56/4 (280-282) &quot;Methylated (beta)-cyclodextrins are Able to Improve the Nasal Absorption of Salmon Calcitonin&quot;, abstract."><meta name="citation_reference" content="Second Declaration of Inventor William Stern Under 37 CFR § 1.132 dated Sep. 7, 2007."><meta name="citation_reference" content="Shao Z., et al., Pharm Res Sep. 1992: 9 (9) : 1157-63, &quot;Cyclodextrins as Nasal Absorption Promoters of Insulin : Mechanistic Evaluations&quot;, abstract."><meta name="citation_reference" content="Stephen G. Farmer and Douglas W.P. Hay, Editors, The Airway Epithelium: Physiology, Pathophysiology and Pharmacology 1991: 3-39, Marcel Dekker, Inc."><meta name="citation_reference" content="Sugibayashi K., et al., J. Pharm. Pharmacol Aug. 1985; 37 (8) : 578-80, &quot;Effect of the Absorption Enhancer, Azone, on the Transport of 5-Fluorouracil Across Hairless Rat Skin&quot;, abstract."><meta name="citation_reference" content="Tengamnuay P., et al., Pharm Res Apr. 1990; 7 (4) : 370-5, &quot;Bile Salt-Fatty Acid Mixed Micelles as Nasal Absorption Promoters of Peptides. II. In vivo Nasal Absorption of Insulin in Rats and Effects of Mixed Micelles on the Morphological Integrity of the Nasal Mucosa&quot;, abstract."><meta name="citation_reference" content="The Merck Index, 13th Edition, 2001, p. 3576."><meta name="citation_reference" content="Third Declaration of inventor William Stern under 37 C.F.R. § 1.132, with Exhibits."><meta name="citation_reference" content="Tyler-Cross et al., &quot;Effects of amino acids sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides&quot;, Journal of Biological Chemistry 266:22549-22556. (1991)."><meta name="citation_reference" content="V. Agarwal et al., &quot;Recent trends in drug delivery systems: intranasal drug delivery&quot;, Indian Journal of Experimental Biology, 37:6-16. (1999)."><meta name="citation_reference" content="Vermehren C:, et al., Drug Metab Dispos Sep. 1997; 25 (9): 1083-8, &quot;Absorption and Metabolism of the Absorption Enhancer Didecanoylphosphatidylcholine in Rabbit Nasal Epithelium in vivo&quot;, abstract."><meta name="citation_reference" content="Wade &amp; Weller, Handbook of Pharmaceutical Excipients, 2nd Edition, American Pharmaceutical Association and the Pharmaceutical Press, pp. 34-37, 122-125, 339-345, 439-440 (1994)."><meta name="citation_reference" content="Windisch, V. et al., &quot;Degradation Pathways of Salmon Calcitonin in Aqueous Solution&quot;, J. Pharm. Sci., 86, 359-364. (1997)."><meta name="citation_patent_number" content="US:RE40812"><meta name="citation_patent_application_number" content="US:10/774,358"><link rel="canonical" href="http://www.google.com/patents/USRE40812"/><meta property="og:url" content="http://www.google.com/patents/USRE40812"/><meta name="title" content="Patent USRE40812 - Liquid pharmaceutical composition for nasal administration comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from citric acid, citric acid salt, and combination thereof, wherein combined concentration of all bioavailability enhancing agents is 10-25 mM"/><meta name="description" content="A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration.A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof."/><meta property="og:title" content="Patent USRE40812 - Liquid pharmaceutical composition for nasal administration comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from citric acid, citric acid salt, and combination thereof, wherein combined concentration of all bioavailability enhancing agents is 10-25 mM"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("46bpU4mIIMiUogSws4DwCA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407464522.0"),"&oggv="+e("es_plusone_gc_20140807.0_p0"),"&ogd=",e("com"),"&ogc=",e("AUS"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("46bpU4mIIMiUogSws4DwCA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407464522.0"),"&oggv="+
d("es_plusone_gc_20140807.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("AUS"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/usRE40812?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/USRE40812"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=5aPIBQABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUSRE40812&amp;usg=AFQjCNEubv2zZXy0Eyl-qc5GEDrkDmtVaw" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/USRE40812.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/USRE40812.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/USRE40812" style="display:none"><span itemprop="description">A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration.A liquid pharmaceutical composition is provided for nasal...</span><span itemprop="url">http://www.google.com/patents/USRE40812?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent USRE40812 - Liquid pharmaceutical composition for nasal administration comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from citric acid, citric acid salt, and combination thereof, wherein combined concentration of all bioavailability enhancing agents is 10-25 mM</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent USRE40812 - Liquid pharmaceutical composition for nasal administration comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from citric acid, citric acid salt, and combination thereof, wherein combined concentration of all bioavailability enhancing agents is 10-25 mM" title="Patent USRE40812 - Liquid pharmaceutical composition for nasal administration comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from citric acid, citric acid salt, and combination thereof, wherein combined concentration of all bioavailability enhancing agents is 10-25 mM"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">USRE40812 E1</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 10/774,358</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Jun 30, 2009</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Feb 5, 2004</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Feb 4, 2000</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2399505A1">CA2399505A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2399505C">CA2399505C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1183965C">CN1183965C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1422160A">CN1422160A</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1251867A1">EP1251867A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1251867A4">EP1251867A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6440392">US6440392</a>, </span><span class="patent-bibdata-value"><a href="/patents/USRE43580">USRE43580</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2001056594A1">WO2001056594A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">10774358, </span><span class="patent-bibdata-value">774358, </span><span class="patent-bibdata-value">US RE40812 E1, </span><span class="patent-bibdata-value">US RE40812E1, </span><span class="patent-bibdata-value">US-E1-RE40812, </span><span class="patent-bibdata-value">USRE40812 E1, </span><span class="patent-bibdata-value">USRE40812E1</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22William+Stern%22">William Stern</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Unigene+Laboratories+Inc.%22">Unigene Laboratories Inc.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/USRE40812.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/USRE40812.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/USRE40812.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (60),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (93),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (4),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (11),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (7)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/RE40812&usg=AFQjCNGfS5wGIqiNvBievJUixpNSVfx_Ug">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3DRE40812&usg=AFQjCNHaOvE-7-1r2E-RllqgcxjrVV1WJA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3DRE40812E1%26KC%3DE1%26FT%3DD&usg=AFQjCNFue0m-fuLEp1JU0-dm5W-XxtTh_Q">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT130055411" lang="EN" load-source="ifi">Liquid pharmaceutical composition for nasal administration comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from citric acid, citric acid salt, and combination thereof, wherein combined concentration of all bioavailability enhancing agents is 10-25 mM</invention-title></span><br><span class="patent-number">US RE40812 E1</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA53264984" lang="EN" load-source="patent-office"> <div num="p-0001" class="abstract">A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration.A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(8)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/USRE40812-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/USRE40812-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/USRE40812-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/USRE40812-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/USRE40812-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/USRE40812-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/USRE40812-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/USRE40812-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/USRE40812-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/USRE40812-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/USRE40812-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/USRE40812-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/USRE40812-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/USRE40812-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/USRE40812-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/USRE40812-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(29)</span></span></div><div class="patent-text"><div mxw-id="PCLM13170937" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-00001" num="00001" class="claim">
      <div class="claim-text">1. A liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid and/or salt thereof in a concentration from 10 to about 50 mM, said composition being in a form suitable for nasal administration.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00002" num="00002" class="claim">
      <div class="claim-text">2. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref> further comprising a pharmaceutically acceptable, aqueous liquid nasal carrier.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00003" num="00003" class="claim">
      <div class="claim-text">3. The liquid pharmaceutical composition of <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein said carrier comprises aqueous saline.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00004" num="00004" class="claim">
      <div class="claim-text">4. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition is in the form of a nasal spray.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00005" num="00005" class="claim">
      <div class="claim-text">5. The liquid pharmaceutical composition of <claim-ref idref="CLM-00004">claim 4</claim-ref> having a viscosity of less than 0.98 cP.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00006" num="00006" class="claim">
      <div class="claim-text">6. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the calcitonin is selected from the group consisting of salmon calcitonin, human calcitonin, porcine calcitonin and 1,7-Asu-ccl calcitonin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00007" num="00007" class="claim">
      <div class="claim-text">7. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the calcitonin is salmon calcitonin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00008" num="00008" class="claim">
      <div class="claim-text">8. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said calcitonin, or salt is present in an amount of from about 100 to about 8,000 MRC units/ml.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00009" num="00009" class="claim">
      <div class="claim-text">9. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said calcitonin, or salt is present in an amount of from about 500 to about 4,000 MRC units/ml.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00010" num="00010" class="claim">
      <div class="claim-text">10. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said calcitonin, or salt is present in an amount of from about 500 to about 3,000 MRC units/ml.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00011" num="00011" class="claim">
      <div class="claim-text">11. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said calcitonin, or salt is present in an amount of from about 1,000 to about 2,500 MRC units/ml.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00012" num="00012" class="claim">
      <div class="claim-text">12. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref> having a pH of from about 3 to about 5.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00013" num="00013" class="claim">
      <div class="claim-text">13. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>A liquid pharmaceutical composition for nasal administration comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from the group consisting of citric acid, citric acid salt and a combination thereof, wherein the combined concentration of all bioavailability enhancing agents is <b>10</b>-<b>25</b> mM, said composition having a pH of from about  3.5 to about  3.9.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00014" num="00014" class="claim">
      <div class="claim-text">14. The liquid pharmaceutical composition of claim <b>1</b> <b>13</b> having a pH of about 3.7.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00015" num="00015" class="claim">
      <div class="claim-text">15. The liquid pharmaceutical composition of <claim-ref idref="CLM-00001">claim 1</claim-ref> having an osmotic pressure of from about 250 to about 350 mOsm/liter.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00016" num="00016" class="claim">
      <div class="claim-text">16. The liquid pharmaceutical composition of claim <b>1</b> <b>13</b> further containing at least 0.1% by weight of polyoxyethylene(20) sorbitan monooleate.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00017" num="00017" class="claim">
      <div class="claim-text">17. The liquid pharmaceutical composition of claim <b>1</b> <b>13</b> further containing at least one preservative selected from the group consisting of benzyl alcohol, phenylethyl alcohol, methyl parabens, ethyl parabens, propyl parabens and butyl parabens.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00018" num="00018" class="claim">
      <div class="claim-text">18. A liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 10 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% polyoxyethylene(20) sorbitan monooleate.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00019" num="00019" class="claim">
      <div class="claim-text">19. A liquid pharmaceutical composition for nasal administration comprising about <b>2,200 MICMRC </b>units of salmon calcitonin, about 20 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% polyoxyethylene(20) sorbitan monooleate.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00020" num="00020" class="claim">
      <div class="claim-text">20. A method of administering a calcitonin to a subject requiring calcitonin treatment, which method comprises administering to said subject a composition as defined in <claim-ref idref="CLM-00001">claim 1</claim-ref> via the nasal route.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00021" num="00021" class="claim">
      <div class="claim-text">21. The method of <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein the amount of calcitonin administered is from about 200 to about 600 MRC units.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00022" num="00022" class="claim">
      <div class="claim-text">22. A method of improving the stability of a liquid pharmaceutical composition of calcitonin comprising adding citric acid or a salt thereof in a concentration from 10 to about 50 mM to said composition.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00023" num="00023" class="claim">
      <div class="claim-text">23. A method of improving the bioavailability or the concentration of plasma calcitonin in a subject following nasal administration of a liquid pharmaceutical composition of calcitonin, which method comprises adding citric acid or a salt thereof in a concentration from 10 to about 50 mM to said composition prior to said administration.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00024" num="00024" class="claim">
      <div class="claim-text">24. The pharmaceutical composition of <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein said citric acid or citric acid salt concentration is <b>20</b> mM.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00025" num="00025" class="claim">
      <div class="claim-text">25. The pharmaceutical composition of <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein said composition includes aqueous saline.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00026" num="00026" class="claim">
      <div class="claim-text">26. The pharmaceutical composition of <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein said composition includes aqueous saline and has an osmotic pressure from <b>250</b> to <b>350</b> mOsm/liter.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00027" num="00027" class="claim">
      <div class="claim-text">27. The pharmaceutical composition of <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein said composition has a viscosity of less than <b>0</b>.<b>98</b> cP.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00028" num="00028" class="claim">
      <div class="claim-text">28. The pharmaceutical composition of <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein said calcitonin is salmon calcitonin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00029" num="00029" class="claim">
      <div class="claim-text">29. The liquid pharmaceutical composition of <claim-ref idref="CLM-00016">claim 16</claim-ref>, further containing at least one preservative selected from the group consisting of benzyl alcohol, phenylethyl alcohol, methyl parabens, ethyl parabens, propyl parabens and butyl parabens.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES18557975" lang="EN" load-source="patent-office" class="description">
    <heading>RELATED APPLICATIONS</heading> <p num="p-0002">This application is based upon and claims priority of U.S. Provisional Application No. 60/180,241, filed Feb. 4, 2000, which is hereby incorporated by reference.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p num="p-0003">1. Field of the Invention</p>
    <p num="p-0004">The present invention relates to an  intranasal pharmaceutical compositions comprising calcitonin as an active ingredient and specific concentrations of citric acid or a salt thereof as a stabilizer and absorption enhancer.</p>
    <p num="p-0005">2. Description of the Related Art</p>
    <p num="p-0006">Calcitonins are a class of polypeptide hormones that are used in the treatment of a variety of conditions including osteoporosis, Pagel's disease and malignant hypercalcemia. They are composed of amino acids and have been extracted from a number of sources including salmon, porcine, eel and human. Calcitonins with amino acid sequences identical to the natural forms have been produced by chemical synthesis as well as by recombinant technology.</p>
    <p num="p-0007">Given their size and chemical composition, calcitonins were originally administered by subcutaneous or intramuscular injection. Other routes of administration were technically difficult because calcitonins were poorly absorbed through tissue and were readily degraded by bodily fluids. Despite these obstacles, a formulation (U.S. Pat. No. 5,759, 565) was developed that could be administered via the nasal route. The nasal formulation was designed to be stored in a multi-dose container that was stable for an extended period of time and resisted bacterial contamination. The preservative in the formulation, benzalkonium chloride, was found to enhance the absorption of salmon calcitonin. However, benzalkonium chloride was reported (P. Graf et al., Clin. Exp. Allergy 25:395-400; 1995) to aggravate rhintisrhinitis medicamentosa in healthy volunteers who were given a decongestant nasal spray containing the preservative. It also had an adverse effect on nasal mucosa (H. Hallen et al., Clin. Exp. Allergy 25:401-405; 1995), Berg et al. (Laryngoscope 104:1153-1158; 1994) disclose that respiratory mucosal tissue that was exposed in vitro underwent severe morphological alterations. Benzalkonium chloride also caused significant slowing of the mucocilary transport velocity in the ex vivo frog palate test (P.C. Braga et al., J. Pharm. Pharmacol. 44:938-940; 1992).</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p num="p-0008">Accordingly, the present invention provides a liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid and/or salt thereof in a concentration from about 10 to about 50 mM, said composition being in a form suitable for nasal administration.</p>
    <p num="p-0009">The present invention also provides a liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 10 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% TWEEN® 80.</p>
    <p num="p-0010">The present invention further provides a liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 20 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benyzl alcohol, and about 0.1% TWEEN® 80.</p>
    <p num="p-0011">The present invention also provides a method of administering a calcitonin to a subject requiring calcitonin treatment, which method comprises administering via the nasal route to said subject a liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about 10 to about 50 mM.</p>
    <p num="p-0012">The present invention further provides a method of improving the stability of a liquid pharmaceutical composition of calcitonin comprising adding citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition.</p>
    <p num="p-0013">The present invention also provides a method of improving the bioavailability or the concentration of plasma calcitonin in a subject following nasal administration of a liquid pharmaceutical composition of calcitonin, which method comprises adding citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition prior to said administration.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p num="p-0014">In accordance with the present invention it has now been surprisingly found that pharmaceutical compositions can be obtained comprising a calcitonin as active ingredient which meet the high standards of stability and bioavailability required for nasal application and which are, for example, eminently suitable for use in multiple dose nasal spray applicators, i.e., applicators capable of delivering a series of individual dosages over, e.g., period of several days or weeks, by the use of citric acid or a salt thereof in concentrations ranging from about 10 to about 50 mM as a buffering agent.</p>
    <p num="p-0015">Surprisingly, it has also been found that use of citric acid or a salt thereof at increasing concentrations confers beneficial advantages in relation to the nasal absorption characteristics of calcitonin containing compositions and hence enhance calcitonin bioavailability levels consequential to nasal application. In addition, it has also been found that the use of citric acid or a salt thereof in concentrations ranging from about 10 to about 50 mM increase the stability of calcitonin containing compositions while at the same time higher concentrations of citric acid or salt thereof did not have the same stabilizing effect.</p>
    <p num="p-0016">The calcitonins for use in the invention may be in free form or in pharmaceutically acceptable salt or complex form, e.g. in pharmaceutically acceptable acid addition salt form. Such salts and complexes are known and possess an equivalent degree of activity and tolerability to the free forms. Suitable acid addition salt forms for use in accordance with the invention include for example the hydrochlorides and acetates.</p>
    <p num="p-0017">The above defined compositions may be applied in accordance with the invention to the nasal mucosa, e.g. either in drop or in spray form. As hereinafter described however, they are most preferably applied in spray form, i.e., in the form of finely divided droplets.</p>
    <p num="p-0018">The compositions of the invention may of course also include additional ingredients, in particular components belonging to the class of conventional pharmaceutically applicable surfactants. In this connection it has in accordance with a further aspect of the present invention been found that the use of surface active agents generally in relation to the nasal application of calcitonins, in particular salmon calcitonin, may increase absorption via the nasal mucosa and hence improve obtained bioavailability rates.</p>
    <p num="p-0019">Preferably, the liquid pharmaceutical calcitonin composition of the present invention contains a pharmaceutically acceptable, a liquid diluent or carrier suitable for application to the nasal mucosa, most preferably aqueous saline.</p>
    <p num="p-0020">The compositions of the invention are formulated so as to permit administration via the nasal route. For this purpose they may also contain, e.g. minimum amounts of any additional ingredients or excipients desired, for example, additional preservatives or, e.g. ciliary stimulants such as caffeine.</p>
    <p num="p-0021">Generally for nasal administration a mildly acid pH will be preferred. Preferably the compositions of the invention have a pH of from about 3 to 5, more preferably from about 3.5 to about 3.9 and most preferably 3.7. Adjustment of the pH is achieved by addition of an appropriate acid, such as hydrochloric acid.</p>
    <p num="p-0022">The compositions of the invention should also possess an appropriate isotonicity and viscosity. Preferably they have an osmotic pressure of from about 260 to about 380 mOsm/liter. Desired viscosity for the nasal spray is preferably less than 0.98 cP. In one embodiment, the osmotic pressure is from <b>250</b> to <b>350</b> mOsm/liter.</p>
    <p num="p-0023">Compositions in accordance with the present invention may also comprise a conventional surfactant, preferably a non-ionic surfactant.</p>
    <p num="p-0024">When a surfactant is employed, the amount present in the compositions of the invention will vary depending on the particular surfactant chosen, the particular mode of administration (e.g. drop or spray) and the effect desired. In general, however, the amount present will be of the order of from about 0.1 mg/ml to about 10 mg/ml, preferably about 0.5 mg/ml to 5 mg/ml and most preferably about 1 mg/ml.</p>
    <p num="p-0025">The amount of calcitonin to be administered in accordance with the method of the invention and hence the amount of active ingredient in the composition of the invention will, of course, depend on the particular calcitonin chosen, the condition to be treated, the desired frequency of administration and the effect desired.</p>
    <p num="p-0026">As indicated in the following examples, bioavailability for calcitonins, in particular salmon calcitonin, as determined in terms of blood-plasma concentration following nasal administration in accordance with the teachings of the present invention has been found to be surprisingly high.</p>
    <p num="p-0027">For nasal administration in accordance with the present invention, treatment will therefore suitably comprise administration of dosages of from about 50 to about 400 MRC units, more preferably from about 100 to about 200 MRC units at a frequency of from about once daily to about three times weekly. Conveniently dosages as aforesaid will be administered in a single application, i.e., treatment will comprise administration of single nasal dosages comprising about 50 to about 400 MRC units, preferably about 100 to about 200 MRC units, calcitonin. Alternatively such dosages may be split over a series of 2 to 4 applications taken at intervals during the day, the dosage at each application then comprising about 10 to about 200, preferably about 25 to about 100 MRC units.</p>
    <p num="p-0028">The total composition quantity administered at each nasal application suitably comprises from about 0.05 to about 0.15 ml, typically about 0.1 ml. Compositions for use in accordance with the invention accordingly suitably comprise from about 150 to about 8,000, preferably from about 500 to about 4,000, more preferably from about 500 to about 3,000, yet again more preferably from about 1,000 to about 2,500, and most preferably about 2,200 MRC units of calcitonin per ml.</p>
    <p num="p-0029">For the purposes of nasal administration, the compositions of the invention will preferably be put up in a container provided with means enabling application of the contained composition to the nasal mucosa, e.g. put up in a nasal applicator device. Suitable applicators are known in the art and include those adapted for administration of liquid compositions to the nasal mucosa in drop or spray form. Since dosaging with calcitonins should be as accurately controlled as possible use of spray applicators for which the administered quantity is susceptible to precise relation will generally be preferred. Suitable administrators include, e.g. atomizing devices, e.g. pump-atomizers and aerosol dispensers. In the latter case, the applicator will contain a composition in accordance with the invention together with a propellant medium suitable for use in a nasal applicator. The atomizing device will be provided with an appropriate spray adaptor allowing delivery of the contained composition to the nasal mucosa. Such devices are well known in the art.</p>
    <p num="p-0030">The container, e.g. nasal applicator, may contain sufficient composition for a single nasal dosaging or for the supply of several sequential dosages, e.g. over a period of days or weeks. Quantities of individual dosages supplied will preferably be as hereinbefore defined. The stability of the compositions of the invention may be determined in conventional manner. As indicated hereinbelow, the calcitonin content of the compositions of the invention will degrade less than 50 % in 15 days at 50° C. as indicated by standard analytical tests.</p>
    <heading>EXPERIMENTAL DESIGN—METHODS OF ADMINISTERING NASAL CALCITONIN</heading> <heading>AND MEASUREMENT OF PLASMA CONCENTRATION</heading> <p num="p-0031">Female Wistar rats, weighing between 225 and 250 g are anesthetized with a combination of ketamine and xyalzine, and a cannula is inserted into the carotid artery. The cannula is fitted to a three-way valve through which blood is sampled and replaced with physiological saline containing herparin. Formulated salmon calcitonin (sCT) (5 μg per 25 μl) is administered intranasally through a micropipette tip that was inserted 8 mm into the rat's nostril. For single-dose studies, 5 μg of sCT was administered. In multiple dose studies, sCT was administered four times in a volume of 25 μl each at 0, 30, 60 and 90 minutes for a total dose of 20 μg.</p>
    <p num="p-0032">In single-dose studies, blood samples are collected prior to dosing and at 5, 15, 30, 60 and 120 minutes after dosing. In multiple-dose studies, blood samples are collected prior to dosing and at 30, 60, 90, 120 and 150 minutes after the administration of the first dose. Blood samples are always collected immediately before the administration of any additional costsdoses.</p>
    <p num="p-0033">Each sample (0.5 ml) of blood is collected into a heparinized 1 ml syringes and then transferred to chilled 1.5 ml polypropylene tubes containing 10 μl of herparin (500 U per ml). The tubes are centrifuged at approximately 3000 rpm for 20 minutes at 2-8° C. and the plasma supernatant is transferred to microcentrifuge tubes that were stored at −20° C. The concentration of sCT in plasma is determined by a competitive radioimmunosaasy. Aliquots of the plasma samples and standards are incubated for 4 hours at room temperature with rabbit anti-sCT antibody. Subsequently, <sup>125</sup>I-sCT is added and incubated overnight at 2-8° C. Antibody-bound <sup>125</sup>I-sCT is isolated the next day by precipitating it with normal rabbit antiserum and goat anti-rabbit antibody. Radioactivity associated with the resulting pellets is measured with a gamma counter. The concentration of sCT in plasma is inversely proportional to the amount of radioactivity that was precipitated.</p>
    <p num="p-0034">The values of Cmax are determined by inspection and the values for bioavailability (relative to an intravenous injection) are calculated from the areas under the curve that were obtained from plots of plasma sCT concentration as a function of time.</p>
    <heading>EXAMPLE 1</heading> <p num="p-0035">The following study examines the effect of the concentration of citric acid on the bioavailability and plasma concentration of nasally administered salmon calcitonin. Rats were administered intranasally as described previously 20 μl of rsCT (200 μg/ml) in 0.85% sodium chloride, 0.1% TWEEN® 80, 0.2% phenylethyl alcohol, 0.5% benzyl alcohol and varying amounts of citric acid adjusted to pH 3.7 at t=0, 20, 60 and 90 minutes. Samples of blood were taken prior to the administration of rsCT at these time points as well as at t=120 and 150 minutes. The resulting plasma samples were analyzed for rsCT by radioimmunosassy. Maximum rsCT levels were detected at t=120 minutes. The results of this study as shown in Table 1 indicate that the bioavailability and peak concentration of rsCT was a function of the concentration of citric acid in the formulation.</p>
    <p num="p-0036">
      <tables id="TABLE-US-00001" num="00001"> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 1</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">EFFECT OF THE CONCENTRATION OF CITRIC ACID</td>
              </tr> <tr class="description-tr"> <td class="description-td">ON THE BIOAVAILABILITY AND PLASMA</td>
              </tr> <tr class="description-tr"> <td class="description-td">CONCENTRATION OF SALMON CALCITONIN</td>
              </tr> <tr class="description-tr"> <td class="description-td">ADMINISTERED INTRANASALLY TO RATS</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="63pt" align="center"> </colspec> <colspec colname="2" colwidth="56pt" align="center"> </colspec> <colspec colname="3" colwidth="98pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Citric acid</td>
                <td class="description-td">Bioavailability</td>
                <td class="description-td">Maximum plasma sCT</td>
              </tr> <tr class="description-tr"> <td class="description-td">(pH 3.7)</td>
                <td class="description-td">(percent ± sdev)</td>
                <td class="description-td">(ng/ml ± sdev)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="63pt" align="char" char="."> </colspec> <colspec colname="2" colwidth="56pt" align="center"> </colspec> <colspec colname="3" colwidth="98pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">0</td>
                <td class="description-td">0.89 ± 0.19</td>
                <td class="description-td">1.10 ± 0.52</td>
              </tr> <tr class="description-tr"> <td class="description-td">10</td>
                <td class="description-td">3.14 ± 1.77</td>
                <td class="description-td">3.66 ± 1.67</td>
              </tr> <tr class="description-tr"> <td class="description-td">25</td>
                <td class="description-td">5.01 ± 2.34</td>
                <td class="description-td">5.11 ± 2.09</td>
              </tr> <tr class="description-tr"> <td class="description-td">50</td>
                <td class="description-td">6.15 ± 1.31</td>
                <td class="description-td">6.05 ± 1.30</td>
              </tr> <tr class="description-tr"> <td class="description-td">100</td>
                <td class="description-td">13.36 ± 3.38 </td>
                <td class="description-td">12.98 ± 3.96 </td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <heading>EXAMPLE 2</heading> <p num="p-0037">The following study examines the effect of different preservatives on the plasma concentration of nasally administered salmon calcitonin. Rats were administered intranasally as described previously 20 μl of sCT (200 μg/ml) in 0.85% sodium chloride, 0.1% TWEEN® 80 and a combination preservatives of either 0.2% phenylethyl alcohol and 0.5% benzyl alcohol or 0.27% methyl parabens and 0.04% proply parabens at t=0, 30, 60 and 90 minutes. The results of this study as shown in Table 2 indicate that the bioavailability and peak concentration of rsCT are not significantly affected by the addition of the different preservatives.</p>
    <p num="p-0038">
      <tables id="TABLE-US-00002" num="00002"> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 2</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">EFFECT OF PRESERVATIVES ON THE</td>
              </tr> <tr class="description-tr"> <td class="description-td">AVAILABILITY AND PLASMA CONCENTRATION</td>
              </tr> <tr class="description-tr"> <td class="description-td">OF SCT ADMINISTERED INTRANASALLY TO RATS</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="84pt" align="left"> </colspec> <colspec colname="2" colwidth="56pt" align="center"> </colspec> <colspec colname="3" colwidth="77pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Bioavailability</td>
                <td class="description-td">Maximum plasma sCT</td>
              </tr> <tr class="description-tr"> <td class="description-td">Preservatives</td>
                <td class="description-td">(percent ± sdev)</td>
                <td class="description-td">(ng/ml ± sdev)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">None</td>
                <td class="description-td">1.14 ± 0.87</td>
                <td class="description-td">1.24 ± 0.79</td>
              </tr> <tr class="description-tr"> <td class="description-td">0.2% phenyethyl alcohol-</td>
                <td class="description-td">0.89 ± 0.19</td>
                <td class="description-td">1.10 ± 0.52</td>
              </tr> <tr class="description-tr"> <td class="description-td">0.5% benzyl alcohol</td>
              </tr> <tr class="description-tr"> <td class="description-td">0.27 methyl parabens-</td>
                <td class="description-td">1.08 ± 0.86</td>
                <td class="description-td">1.47 ± 1.46</td>
              </tr> <tr class="description-tr"> <td class="description-td">0.04% propyl parabens</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <heading>EXAMPLE 3</heading> <p num="p-0039">The following study examines the effect of the concentration of citric acid on the stability of salmon calcitonin stored for varying periods at a temperature of 50° C. Nasal formulations containing sCT (200 μg/ml), 0.25% phenylethyl alcohol, 0.5% benzyl alcohol and 0.1% TWEEN® 80 were adjusted to pH 3.7 with either HCl or the indicated amount of buffered citric acid. The formulations were stored at 50° C. in sealed glass containers for the indicated amount of time and analyzed for sCT by high performance liquid chromatography. The results as shown in Table 3 indicate that in the absence of citric acid, the amount sCT in the formulation decreased steadily between 0 and 9 days after the study was begun. In the presence of citric acid (10-50 mM) the rate of disappearance of sCT decreased significantly. However, as the concentration of citric acid was further increased, the rate of sCT disappearance from vials stored at 50° C. increased in proportion to the amount of buffered citric acid in the formulation.</p>
    <p num="p-0040">
      <tables id="TABLE-US-00003" num="00003"> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 3</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">EFFECT OF THE CONCENTRATION OF</td>
              </tr> <tr class="description-tr"> <td class="description-td">CITRIC ACID ON THE STABILITY OF</td>
              </tr> <tr class="description-tr"> <td class="description-td">sCT STORED FOR VARYING PERIODS AT 50° C.</td>
              </tr> <tr class="description-tr"> <td class="description-td">Percent sCT Recovered</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="35pt" align="center"> </colspec> <colspec colname="2" colwidth="182pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Days at</td>
                <td class="description-td">Citric Acid (pH 3.7)</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="6"> <colspec colname="1" colwidth="35pt" align="center"> </colspec> <colspec colname="2" colwidth="35pt" align="center"> </colspec> <colspec colname="3" colwidth="35pt" align="center"> </colspec> <colspec colname="4" colwidth="35pt" align="center"> </colspec> <colspec colname="5" colwidth="35pt" align="center"> </colspec> <colspec colname="6" colwidth="42pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">50° C.</td>
                <td class="description-td">0 Mm</td>
                <td class="description-td">10 mM</td>
                <td class="description-td">20 mM</td>
                <td class="description-td">50 mM</td>
                <td class="description-td">100 mM</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="6"> <colspec colname="1" colwidth="35pt" align="center"> </colspec> <colspec colname="2" colwidth="35pt" align="char" char="."> </colspec> <colspec colname="3" colwidth="35pt" align="char" char="."> </colspec> <colspec colname="4" colwidth="35pt" align="char" char="."> </colspec> <colspec colname="5" colwidth="35pt" align="char" char="."> </colspec> <colspec colname="6" colwidth="42pt" align="char" char="."> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">9</td>
                <td class="description-td">100</td>
                <td class="description-td">100</td>
                <td class="description-td">100</td>
                <td class="description-td">100</td>
                <td class="description-td">100</td>
              </tr> <tr class="description-tr"> <td class="description-td">3</td>
                <td class="description-td">83</td>
                <td class="description-td">94</td>
                <td class="description-td">91</td>
                <td class="description-td">90</td>
                <td class="description-td">87</td>
              </tr> <tr class="description-tr"> <td class="description-td">6</td>
                <td class="description-td">53</td>
                <td class="description-td">90</td>
                <td class="description-td">87</td>
                <td class="description-td">83</td>
                <td class="description-td">77</td>
              </tr> <tr class="description-tr"> <td class="description-td">9</td>
                <td class="description-td">24</td>
                <td class="description-td">82</td>
                <td class="description-td">78</td>
                <td class="description-td">73</td>
                <td class="description-td">66</td>
              </tr> <tr class="description-tr"> <td class="description-td">15 </td>
                <td class="description-td">22</td>
                <td class="description-td">74</td>
                <td class="description-td">68</td>
                <td class="description-td">61</td>
                <td class="description-td">20</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4151276">US4151276</a></td><td class="patent-data-table-td patent-date-value">May 12, 1975</td><td class="patent-data-table-td patent-date-value">Apr 24, 1979</td><td class="patent-data-table-td ">Armour Pharmaceutical Company</td><td class="patent-data-table-td ">Method of suppressing gastric acid secretion by the oral administration of calcitonin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4690952">US4690952</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 1985</td><td class="patent-data-table-td patent-date-value">Sep 1, 1987</td><td class="patent-data-table-td ">Yamanouchi Pharmaceutical Co., Inc.</td><td class="patent-data-table-td ">Pharmaceutical compositions for nasal administration comprising calcitonin and an absorption-promoting substance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4788221">US4788221</a></td><td class="patent-data-table-td patent-date-value">May 5, 1987</td><td class="patent-data-table-td patent-date-value">Nov 29, 1988</td><td class="patent-data-table-td ">Yamanouchi Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising calcitonin and an absorption-promoting substance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4845080">US4845080</a></td><td class="patent-data-table-td patent-date-value">Sep 26, 1986</td><td class="patent-data-table-td patent-date-value">Jul 4, 1989</td><td class="patent-data-table-td ">Ciba-Geigy Corporation</td><td class="patent-data-table-td ">Human calcitonin peptide with salmon calcitonin-like characteristics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4900730">US4900730</a></td><td class="patent-data-table-td patent-date-value">Jun 18, 1987</td><td class="patent-data-table-td patent-date-value">Feb 13, 1990</td><td class="patent-data-table-td ">Toyo Jozo Co., Ltd.</td><td class="patent-data-table-td ">Preparation which promotes the absorption of peptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5023252">US5023252</a></td><td class="patent-data-table-td patent-date-value">Dec 8, 1989</td><td class="patent-data-table-td patent-date-value">Jun 11, 1991</td><td class="patent-data-table-td ">Conrex Pharmaceutical Corporation</td><td class="patent-data-table-td ">Using heterocyclic oxygen, sulfur, or nitrogen containing compound</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5026825">US5026825</a></td><td class="patent-data-table-td patent-date-value">Sep 8, 1988</td><td class="patent-data-table-td patent-date-value">Jun 25, 1991</td><td class="patent-data-table-td ">Rhone-Poulenc Rorer Pharmaceuticals Inc.</td><td class="patent-data-table-td ">With aminolevulinic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5059587">US5059587</a></td><td class="patent-data-table-td patent-date-value">Jul 19, 1988</td><td class="patent-data-table-td patent-date-value">Oct 22, 1991</td><td class="patent-data-table-td ">Toyo Jozo Company, Ltd.</td><td class="patent-data-table-td ">Physiologically active peptide composition for nasal administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5124315">US5124315</a></td><td class="patent-data-table-td patent-date-value">Jun 17, 1991</td><td class="patent-data-table-td patent-date-value">Jun 23, 1992</td><td class="patent-data-table-td ">Phideatech S.R.L.</td><td class="patent-data-table-td ">Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5183802">US5183802</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 1988</td><td class="patent-data-table-td patent-date-value">Feb 2, 1993</td><td class="patent-data-table-td ">Isf Societa Per Azioni</td><td class="patent-data-table-td ">Mixed with nontoxic effective amount of adsorption enhancer-ammonium glycyrrhizinate and a carrier; used as nose sprays for treatment of osteoporosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5234906">US5234906</a></td><td class="patent-data-table-td patent-date-value">Jan 10, 1991</td><td class="patent-data-table-td patent-date-value">Aug 10, 1993</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Hyperglycemic compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5279836">US5279836</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 1992</td><td class="patent-data-table-td patent-date-value">Jan 18, 1994</td><td class="patent-data-table-td ">Mediator S.R.L.</td><td class="patent-data-table-td ">Topical application</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5281580">US5281580</a></td><td class="patent-data-table-td patent-date-value">Jul 23, 1991</td><td class="patent-data-table-td patent-date-value">Jan 25, 1994</td><td class="patent-data-table-td ">Toyo Jozo Company, Ltd.</td><td class="patent-data-table-td ">Respiratory system disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5310727">US5310727</a></td><td class="patent-data-table-td patent-date-value">Nov 30, 1990</td><td class="patent-data-table-td patent-date-value">May 10, 1994</td><td class="patent-data-table-td ">Scalvo S.P.A.</td><td class="patent-data-table-td ">And human albumin, storage stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5496801">US5496801</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 1993</td><td class="patent-data-table-td patent-date-value">Mar 5, 1996</td><td class="patent-data-table-td ">Allelix Biopharmaceuticals Inc.</td><td class="patent-data-table-td ">Storage stability, mannitol, citric acid buffer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5514365">US5514365</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 1994</td><td class="patent-data-table-td patent-date-value">May 7, 1996</td><td class="patent-data-table-td ">Schiapparelli Salute S.P.A.</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising calcitonin for intranasal administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5534496">US5534496</a></td><td class="patent-data-table-td patent-date-value">Mar 29, 1994</td><td class="patent-data-table-td patent-date-value">Jul 9, 1996</td><td class="patent-data-table-td ">University Of Southern California</td><td class="patent-data-table-td ">Methods and compositions to enhance epithelial drug transport</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5536508">US5536508</a></td><td class="patent-data-table-td patent-date-value">Oct 21, 1993</td><td class="patent-data-table-td patent-date-value">Jul 16, 1996</td><td class="patent-data-table-td ">Vectorpharma International S.P.A.</td><td class="patent-data-table-td ">Biodegradable polymer and polysaccharide gel and bioadhesive with drug</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5571788">US5571788</a></td><td class="patent-data-table-td patent-date-value">Jan 24, 1994</td><td class="patent-data-table-td patent-date-value">Nov 5, 1996</td><td class="patent-data-table-td ">Ciba-Geigy Corporation</td><td class="patent-data-table-td ">Stable calcitonin pharmaceutical compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5593962">US5593962</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 1993</td><td class="patent-data-table-td patent-date-value">Jan 14, 1997</td><td class="patent-data-table-td ">Ciba-Geigy Corporation</td><td class="patent-data-table-td ">Treating calcium deficiency</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5637309">US5637309</a></td><td class="patent-data-table-td patent-date-value">Sep 20, 1994</td><td class="patent-data-table-td patent-date-value">Jun 10, 1997</td><td class="patent-data-table-td ">Shiseido Company, Ltd.</td><td class="patent-data-table-td ">Including carrier composed of combination of cellulose ether or crystalline cellulose with fat, oil, wax, fatty acid, saccharide and/or polyacrylate ester; for intrathecal implantation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5654000">US5654000</a></td><td class="patent-data-table-td patent-date-value">Jul 17, 1996</td><td class="patent-data-table-td patent-date-value">Aug 5, 1997</td><td class="patent-data-table-td ">Poli Industria Chimica S.P.A.</td><td class="patent-data-table-td ">Liquid mixture of a liposomic dispersion containing a drug and a thermosetting ethylene oxide-propylene oxide copolymer, sustained release</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5665700">US5665700</a></td><td class="patent-data-table-td patent-date-value">Aug 15, 1994</td><td class="patent-data-table-td patent-date-value">Sep 9, 1997</td><td class="patent-data-table-td ">Skua Investments Limited</td><td class="patent-data-table-td ">Pharmaceutical formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5693608">US5693608</a></td><td class="patent-data-table-td patent-date-value">Feb 28, 1995</td><td class="patent-data-table-td patent-date-value">Dec 2, 1997</td><td class="patent-data-table-td ">Bechgaard International Research And Development A/S</td><td class="patent-data-table-td ">Method of administering a biologically active substance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5700486">US5700486</a></td><td class="patent-data-table-td patent-date-value">Apr 30, 1996</td><td class="patent-data-table-td patent-date-value">Dec 23, 1997</td><td class="patent-data-table-td ">Vectorpharma International S.P.A.</td><td class="patent-data-table-td ">Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5714477">US5714477</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 1994</td><td class="patent-data-table-td patent-date-value">Feb 3, 1998</td><td class="patent-data-table-td ">Pharmacia &amp; Upjohn Aktiebolag</td><td class="patent-data-table-td ">Homogenous, aqueous solution containing fatty monoglyceride; enhanced absorption/bioavailability, drug delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5719122">US5719122</a></td><td class="patent-data-table-td patent-date-value">Oct 15, 1993</td><td class="patent-data-table-td patent-date-value">Feb 17, 1998</td><td class="patent-data-table-td ">Smithkline Beecham Farmaceutici S.P.A.</td><td class="patent-data-table-td ">Enhancing transdermal or transmucosal absorption by administering with a saturated polyglycolysed glyceride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5725871">US5725871</a></td><td class="patent-data-table-td patent-date-value">Jun 15, 1994</td><td class="patent-data-table-td patent-date-value">Mar 10, 1998</td><td class="patent-data-table-td ">Danbiosyst Uk Limited</td><td class="patent-data-table-td ">Drug delivery compositions comprising lysophosphoglycerolipid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5726154">US5726154</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 1996</td><td class="patent-data-table-td patent-date-value">Mar 10, 1998</td><td class="patent-data-table-td ">University Of Utah Research Foundation</td><td class="patent-data-table-td ">Stabilization and oral delivery of calcitonin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5733569">US5733569</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 6, 1995</td><td class="patent-data-table-td patent-date-value">Mar 31, 1998</td><td class="patent-data-table-td ">Novartis Corporation</td><td class="patent-data-table-td ">Galenic compositions comprising calcitonin and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5733572">US5733572</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 1994</td><td class="patent-data-table-td patent-date-value">Mar 31, 1998</td><td class="patent-data-table-td ">Imarx Pharmaceutical Corp.</td><td class="patent-data-table-td ">Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5759565">US5759565</a></td><td class="patent-data-table-td patent-date-value">Dec 31, 1991</td><td class="patent-data-table-td patent-date-value">Jun 2, 1998</td><td class="patent-data-table-td ">Novartis Corporation</td><td class="patent-data-table-td ">Galenic compositions comprising calcitonin and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5759566">US5759566</a></td><td class="patent-data-table-td patent-date-value">Jun 17, 1996</td><td class="patent-data-table-td patent-date-value">Jun 2, 1998</td><td class="patent-data-table-td ">Poli Industria Chimica Spa</td><td class="patent-data-table-td ">Ethylene oxide-propylene oxide copolymer thickener</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5776886">US5776886</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 1994</td><td class="patent-data-table-td patent-date-value">Jul 7, 1998</td><td class="patent-data-table-td ">Teikoku Seiyaku Kabushiki Kaisha</td><td class="patent-data-table-td ">Intravaginal preparation containing physiologically active peptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5858391">US5858391</a></td><td class="patent-data-table-td patent-date-value">May 28, 1997</td><td class="patent-data-table-td patent-date-value">Jan 12, 1999</td><td class="patent-data-table-td ">Kv Pharmaceutical Company</td><td class="patent-data-table-td ">Long acting GI and esophageal protectant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5912014">US5912014</a></td><td class="patent-data-table-td patent-date-value">Mar 15, 1996</td><td class="patent-data-table-td patent-date-value">Jun 15, 1999</td><td class="patent-data-table-td ">Unigene Laboratories, Inc.</td><td class="patent-data-table-td ">Oral salmon calcitonin pharmaceutical products</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5938654">US5938654</a></td><td class="patent-data-table-td patent-date-value">Feb 1, 1995</td><td class="patent-data-table-td patent-date-value">Aug 17, 1999</td><td class="patent-data-table-td ">Alza Corporation</td><td class="patent-data-table-td ">Osmotic device for delayed delivery of agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5968899">US5968899</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 1995</td><td class="patent-data-table-td patent-date-value">Oct 19, 1999</td><td class="patent-data-table-td ">Tsumura &amp; Co.</td><td class="patent-data-table-td ">Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6008189">US6008189</a></td><td class="patent-data-table-td patent-date-value">Jan 21, 1998</td><td class="patent-data-table-td patent-date-value">Dec 28, 1999</td><td class="patent-data-table-td ">Teikoku Seiyaku Kabushiki Kaisha</td><td class="patent-data-table-td ">Intravaginal preparation containing physiologically active peptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6017538">US6017538</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 1993</td><td class="patent-data-table-td patent-date-value">Jan 25, 2000</td><td class="patent-data-table-td ">Institut Pasteur</td><td class="patent-data-table-td ">Plasmodium falciparum antigens inducing protective antibodies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6086918">US6086918</a></td><td class="patent-data-table-td patent-date-value">Mar 14, 1997</td><td class="patent-data-table-td patent-date-value">Jul 11, 2000</td><td class="patent-data-table-td ">Unigene Laboratories, Inc.</td><td class="patent-data-table-td ">Releasing peptide active agent, with ph lowering agent and an absorption enhancer into patient&#39;s intestine through mouth and stomach under protection of an acid resistant vehicle which prevents contact between stomach protease and peptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6087338">US6087338</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 1997</td><td class="patent-data-table-td patent-date-value">Jul 11, 2000</td><td class="patent-data-table-td ">Therapicon S.R.L.</td><td class="patent-data-table-td ">Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6107277">US6107277</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 1997</td><td class="patent-data-table-td patent-date-value">Aug 22, 2000</td><td class="patent-data-table-td ">Therapicon S.R.L.</td><td class="patent-data-table-td ">Calcitonin salmon analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6149893">US6149893</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 1999</td><td class="patent-data-table-td patent-date-value">Nov 21, 2000</td><td class="patent-data-table-td ">Alfa Wassermann S.P.A.</td><td class="patent-data-table-td ">Pharmaceutical compositions containing calcitonin in a spray dosing feeder for intranasal administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6153582">US6153582</a></td><td class="patent-data-table-td patent-date-value">Nov 5, 1998</td><td class="patent-data-table-td patent-date-value">Nov 28, 2000</td><td class="patent-data-table-td ">Bausch &amp; Lomb Surgical, Inc.</td><td class="patent-data-table-td ">Defined serumfree medical solution for ophthalmology</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6348207">US6348207</a></td><td class="patent-data-table-td patent-date-value">Sep 30, 1997</td><td class="patent-data-table-td patent-date-value">Feb 19, 2002</td><td class="patent-data-table-td ">Emisiphere Technologies, Inc.</td><td class="patent-data-table-td ">Exposing biologically active agent to complexing perturbant to reversibly transform biologically active agent to intermediate state and form orally deliverable supramolecular complex, orally administering complex to subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6440392">US6440392</a></td><td class="patent-data-table-td patent-date-value">Feb 2, 2001</td><td class="patent-data-table-td patent-date-value">Aug 27, 2002</td><td class="patent-data-table-td ">Unigene Laboratories, Inc.</td><td class="patent-data-table-td ">Citric acid or salt stabilized solution; high bioavail-ability; treatment of conditions including osteoporosis, paget&#39;s disease and malignant hypercalcemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6440446">US6440446</a></td><td class="patent-data-table-td patent-date-value">Apr 16, 1999</td><td class="patent-data-table-td patent-date-value">Aug 27, 2002</td><td class="patent-data-table-td ">Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo</td><td class="patent-data-table-td ">Agent for anti-osteoporosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6447785">US6447785</a></td><td class="patent-data-table-td patent-date-value">Nov 2, 2000</td><td class="patent-data-table-td patent-date-value">Sep 10, 2002</td><td class="patent-data-table-td ">Allergan Sales, Inc.</td><td class="patent-data-table-td ">Method for treating hypercalcemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6509006">US6509006</a></td><td class="patent-data-table-td patent-date-value">Oct 26, 1999</td><td class="patent-data-table-td patent-date-value">Jan 21, 2003</td><td class="patent-data-table-td ">Inhale Therapeutic Systems, Inc.</td><td class="patent-data-table-td ">Readily and reliably dispersible dry powder biocompatible particles of alpha-1-antitrypsin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0115627A1?cl=en">EP0115627A1</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 1983</td><td class="patent-data-table-td patent-date-value">Aug 15, 1984</td><td class="patent-data-table-td ">Armour Pharmaceutical Company</td><td class="patent-data-table-td ">Enhancement of intranasal absorption of calcitonin by formulation with surfactants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0327756A2?cl=en">EP0327756A2</a></td><td class="patent-data-table-td patent-date-value">Nov 10, 1988</td><td class="patent-data-table-td patent-date-value">Aug 16, 1989</td><td class="patent-data-table-td ">Smithkline Beecham Farmaceutici S.p.A.</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising a calcitonin and a glycyrrhizinate as absorption enhancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0358234A2?cl=en">EP0358234A2</a></td><td class="patent-data-table-td patent-date-value">Sep 8, 1989</td><td class="patent-data-table-td patent-date-value">Mar 14, 1990</td><td class="patent-data-table-td ">Rhone-Poulenc Rorer International (Holdings) Inc.</td><td class="patent-data-table-td ">Intranasal calcitonin formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0371010A1?cl=en">EP0371010A1</a></td><td class="patent-data-table-td patent-date-value">Nov 26, 1985</td><td class="patent-data-table-td patent-date-value">May 30, 1990</td><td class="patent-data-table-td ">Yamanouchi Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Absorbable calcitonin medicament</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0418697A1?cl=en">EP0418697A1</a></td><td class="patent-data-table-td patent-date-value">Sep 10, 1990</td><td class="patent-data-table-td patent-date-value">Mar 27, 1991</td><td class="patent-data-table-td ">ESSETI s.a.s. LABORATORIO CHIMICO FARMACO BIOLOGICO DI A. IEVOLI &amp;amp; C.</td><td class="patent-data-table-td ">Pharmaceutical compositions containing calcitonin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0489217A1?cl=en">EP0489217A1</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 1990</td><td class="patent-data-table-td patent-date-value">Jun 10, 1992</td><td class="patent-data-table-td ">Dr. A. Tosi Farmaceutici S.R.L.</td><td class="patent-data-table-td ">Calcitonin compositions for intranasal administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0726075A1?cl=en">EP0726075A1</a></td><td class="patent-data-table-td patent-date-value">Feb 8, 1995</td><td class="patent-data-table-td patent-date-value">Aug 14, 1996</td><td class="patent-data-table-td ">Therapicon Srl</td><td class="patent-data-table-td ">Pharmaceutical non-inorganic saline solutions for endonasal administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0809512A1?cl=en">EP0809512A1</a></td><td class="patent-data-table-td patent-date-value">Feb 8, 1996</td><td class="patent-data-table-td patent-date-value">Dec 3, 1997</td><td class="patent-data-table-td ">Therapicon Srl</td><td class="patent-data-table-td ">Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=5aPIBQABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DGB%26NR%3D2092002A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNGG6q3g6-172kV3EUXqvVbrTER5Mw">GB2092002A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=5aPIBQABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DJP%26NR%3DH0578258A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNHdUJ3jHQhlC2LW0zEs-D47AWIu4A">JPH0578258A</a></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">A.E. Pontiroli, et al., Intranasal calcitonin and plasma calcium concentrations in normal subjects, British Medical Journal, Clinical Research ed., 290:1390-1391. (1985).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Abe K., et al., Chem. Pharm. Bull (Tokyo) Dec. 1995; 43 (12): 2232-7, "<a href='http://scholar.google.com/scholar?q="Enhanced+Nasal+Delivery+of+Luteinizing+Hormone+Releasing+Agonist+Buserelin+by+Oleic+Acid+Solubilized+and+Stabilized+in+Hydroxypropyl-beta-cyclodextrin"'>Enhanced Nasal Delivery of Luteinizing Hormone Releasing Agonist Buserelin by Oleic Acid Solubilized and Stabilized in Hydroxypropyl-beta-cyclodextrin</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Agerholm C., et al., J. Pharm. Sci. Dec. 1994; 83 (12) : 1706-11, "<a href='http://scholar.google.com/scholar?q="Epithelial+Transport+and+Bioavailability+of+Intranasally+Administered+Human+Growth+Hormone+Formulated+with+the+Absorption+Enhancers+Didecanoyl-L-alpha-phosphatidylcholine+and+alpha-cyclodextrin+in+Rabbits"'>Epithelial Transport and Bioavailability of Intranasally Administered Human Growth Hormone Formulated with the Absorption Enhancers Didecanoyl-L-alpha-phosphatidylcholine and alpha-cyclodextrin in Rabbits</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Akers and DeFelippis, Pharmaceutical Formulation Development of Peptides and Proteins, (published 2000), Sven Frokjaer and Lars Hovgaard, Editors Pharmaceutical Formulation Development of Peptides and Proteins, pp. 145-177, CRC Press 2000.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Akwete Lex Adjei and Pramod K. Gupta, Editors, Inhalation Delivery of Therapeutic Peptides and Proteins, 1997:493-514, Marcel Dekker, Inc.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Amended Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims, Unigene Laboratories, Inc. et at. v. Apotex, Inc., et al., Civil Action No. 06-CV-5571-RPP-THK EFC Case (S.D.N.Y.), May 8, 2007.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims, Unigene Laboratories Inc., et al. v. Apotex Inc., et al., Civil Action No. 06-CV-5571-RPP-THK, EFC Case (S.D.N.Y.) Sep. 20, 2006.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Apotex Notice Letter-Jun. 1, 2006.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Armyn P. Sayani, et al. "<a href='http://scholar.google.com/scholar?q="Systemic+Delivery+of+Peptides+and+Proteins+Across+Absorptive+Mucoase"'>Systemic Delivery of Peptides and Proteins Across Absorptive Mucoase</a>", Critical Reviews in Therapeutic Drug Carrier Systems, 13 (1&amp;2):85-184 at pp. 106,127,128,144,158,160 (1996).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bell, L.N., "<a href='http://scholar.google.com/scholar?q="Peptide+stability+in+solids+and+solutions"'>Peptide stability in solids and solutions</a>", Biotechnology Progress 13:342-346. (1997).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Berg et al., Laryngoscope 104:1153-1158; 1994 "<a href='http://scholar.google.com/scholar?q="The+Effect+of+Decongestive+Nosedrops+on+Human+Respiratory+Mucosa+In+Vitro"'>The Effect of Decongestive Nosedrops on Human Respiratory Mucosa In Vitro</a>".</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Biotechnology Newswatch, vol. 9, No. 12; p. 1, "<a href='http://scholar.google.com/scholar?q="Two-nasally+delivered+CalBio+hormones+pass+initial+clinicals"'>Two-nasally delivered CalBio hormones pass initial clinicals</a>", Jun. 19, 1989.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Caspar W.R., et al. , Drug &amp; Cosmetic Industry, vol. 156; No. 1; p. 46, "<a href='http://scholar.google.com/scholar?q="New+Ways+of+Enhancing+the+Delivery+of+Skin+Care+Ingredients"'>New Ways of Enhancing the Delivery of Skin Care Ingredients</a>", Jan. 1995.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Complaint by Unigene Laboratories, Inc. et at. v. Apotex, Inc., et al., 06-cv-5571-RPP-THK (EFC Case)-U.S. District Court for the Southern District of New York.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Critchley H., et al., J. Pharm Pharmacol Aug. 1994; 46 (8) : 651-6, "<a href='http://scholar.google.com/scholar?q="Nasal+Absorption+of+Desmpressin+in+Rats+and+Sheep.+Effect+of+A+Bioadhesive+Microsphere+Delivery+System"'>Nasal Absorption of Desmpressin in Rats and Sheep. Effect of A Bioadhesive Microsphere Delivery System</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">D. Harris, et al., "<a href='http://scholar.google.com/scholar?q="Bioadhesive+polymers+in+peptide+drug+delivery"'>Bioadhesive polymers in peptide drug delivery</a>", Biomaterials, 11:652-658. (1990).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">D. Voet and J.G. Voet, Biochemistry, 2nd Edition, John Wiley &amp; Sons, New York, pp. 538-541 (1995).</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Database WPI, Section Ch, Week 199317, Derwent Publications Ltd., London, GB; Class B04, AN 1993-140304, XP002300282 &amp; JP 05 078258 A (Suntory) Mar. 30, 1993.</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Ashim K. Mitra, Ph.D. Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK.</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Michael Sofocleous dated Oct. 13, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Professor Alexander M. Klibanov Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK.</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Professor Robert S. Langer Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK.</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Donovan M.D., et al., Pharm. Res. Aug. 1990; 7 (8) : 808-15, "<a href='http://scholar.google.com/scholar?q="The+Molecular+Weight+Dependence+of+Nasal+Absorption%3A+the+Effect+of+Absorption+Enhancers"'>The Molecular Weight Dependence of Nasal Absorption: the Effect of Absorption Enhancers</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dua et al., International Journal of Pharmaceutics 147, 1997, pp. 233-242 "<a href='http://scholar.google.com/scholar?q="The+influence+of+tonicity+and+viscosity+on+the+intranasal+absorption+of+salmon+calcitonin+in+rabbits."'>The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits.</a>"</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">European Search Report dated Oct. 10, 2004.</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Dr. Robert P. Raymond, Esq., dated Dec. 2, 2008, pp. 1-23.</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Henry Kwan, Ph.D. Regarding Validity of U.S. Pat. No. 6,440,392, dated Dec. 2, 2008, pp. 1-182.</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Feb. 20, 2008 Defendants'<a href='http://scholar.google.com/scholar?q="+Notice+of+Motion+in+Support+of+Defendants%27+Motion+For+Reconsideration+of+the+Feb.+4%2C+2008+Order+Regarding+Defendants"'> Notice of Motion in Support of Defendants' Motion For Reconsideration of the Feb. 4, 2008 Order Regarding Defendants</a>' Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Feb. 20, 2008 Memorandum of Law in Support of Defendants'<a href='http://scholar.google.com/scholar?q="+Motion+for+Reconsideration+of+the+of+the+Feb.+4%2C+2008+Order+Regarding+Defendants"'> Motion for Reconsideration of the of the Feb. 4, 2008 Order Regarding Defendants</a>' Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Feb. 28, 2008 Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Feb. 4, 2008 Opinion and Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">H. Hallen et al., Clin. Exp. Allergy, vol. 25:401-405; 1995 "<a href='http://scholar.google.com/scholar?q="Benzalkonium+chloride+in+nasal+decongestive+sprays+has+a+long-lasting+adverse+effect+on+the+nasal+mucosa+of+healthy+volunteers"'>Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers</a>".</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hayashi, et al., "<a href='http://scholar.google.com/scholar?q="Physiological+mechanism+for+enhancement+of+paracellular+drug+transport"'>Physiological mechanism for enhancement of paracellular drug transport</a>", Journal of Controlled Release, 62: 141-148. (1999).</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hosoya K., et al., Biol Pharm Bull Feb. 1994; 17 (2) : 316-22, "<a href='http://scholar.google.com/scholar?q="Evaluation+of+Enhancers+to+Increase+Nasal+Absorption+Using+Ussing+Chamber+Technique"'>Evaluation of Enhancers to Increase Nasal Absorption Using Ussing Chamber Technique</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jacobs M.A., et al., Diabetes Nov. 1993; 41 (11) : 1649-55, "<a href='http://scholar.google.com/scholar?q="The+pharmacodynamics+and+activity+of+intranasally+administered+insulin+in+healthy+male+volunteers"'>The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jul. 14, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jul. 15, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jul. 16, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kagatani S., et al., Pharm. Res. 1996 13/5 (739-743), "<a href='http://scholar.google.com/scholar?q="Enhancement+of+Nasal+Salmon+Calcitonin+Absorption+by+Lauroyclarnitine+Chloride+in+Rats"'>Enhancement of Nasal Salmon Calcitonin Absorption by Lauroyclarnitine Chloride in Rats</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kobayashi, S., et al., "<a href='http://scholar.google.com/scholar?q="Pulmonary+delivery+of+salmon+calcitonin+dry+powders+containing+absorption+enhancers+in+rats"'>Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats</a>", Pharmaceutical Research, 13:80-83. (1996).</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kurosaki Y., et al., J. Pharmacobiodyn Dec. 1988; 11 (12) : 824-32, "<a href='http://scholar.google.com/scholar?q="Application+of+Propranolol+to+the+Keratinized+Oral+Mucosa%3A+Avoidance+of+First-Pass+Elimination+and+the+Use+of+1-Dodecylazacycloheptan-2-one+%28Azone%29+as+an+Absorption+Enhancer+of+Bioadhesive+Film-Dosage+Form"'>Application of Propranolol to the Keratinized Oral Mucosa: Avoidance of First-Pass Elimination and the Use of 1-Dodecylazacycloheptan-2-one (Azone) as an Absorption Enhancer of Bioadhesive Film-Dosage Form</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lee, K.C. et al., "<a href='http://scholar.google.com/scholar?q="Degradation+of+synthetic+salmon+calcitonin+in+aqueous+solutions"'>Degradation of synthetic salmon calcitonin in aqueous solutions</a>", Pharm. Res. 9:1521-1523. (1992).</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Li, Y., et al., "<a href='http://scholar.google.com/scholar?q="Effect+of+a+conjugated+bile+salt+on+the+pulmonary+absorption+of+insulin+in+rats"'>Effect of a conjugated bile salt on the pulmonary absorption of insulin in rats</a>", Eur. J. Pharm. Biopharm, 39:216-21. (1993).</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">M. Gibson, Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commerical Dosage Form, p. 479 and Chapter 13, Aqueous Nasal Dosage Forms, Ed., Taylor &amp; Francis. (2001).</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">M. Weiner and I. Leonard Bernstein, 1989, Adverse Reactions to Drug Formulation Agents, A Handbook of Excipients, Marcel Dekker, Inc. 1989, pp. 361-363 and 390-391.</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">M.J. Cho., et al., "<a href='http://scholar.google.com/scholar?q="Citric+acid+as+an+adjuvant+for+transepithelial+transport"'>Citric acid as an adjuvant for transepithelial transport</a>" International Journal of Pharmaceutics, 52:79-81. (1989).</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Martin E., et al., Pharm Res May 1997; 14(5) : 631-7, "<a href='http://scholar.google.com/scholar?q="Confocal+laser+scanning+microscopic+visualization+of+the+transport+of+Dextrans+after+Nasal+Administration+to+Rats%3A+Effects+of+Absorption+Enhancers"'>Confocal laser scanning microscopic visualization of the transport of Dextrans after Nasal Administration to Rats: Effects of Absorption Enhancers</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Marttin E., Pharm. Res., May 1997, 14 (5): 631-7, "<a href='http://scholar.google.com/scholar?q="Confocal+Laser+Scanning+Microscopic+Visualization+of+the+Transport+of+Dextrans+After+Nasal+Administration+to+Rats%3A+Effects+of+Absorption+Enhancers"'>Confocal Laser Scanning Microscopic Visualization of the Transport of Dextrans After Nasal Administration to Rats: Effects of Absorption Enhancers</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Morimoto K., et al., J. Pharma. Pharmacol. 1985 37/2 (134-136) "<a href='http://scholar.google.com/scholar?q="Enhancement+of+Nasal+Absorption+of+Insulin+and+Calcitonin+Using+Polyacrylic+Acid+Gel"'>Enhancement of Nasal Absorption of Insulin and Calcitonin Using Polyacrylic Acid Gel</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Morimoto K., et al., Pharm Res Sep. 1991; 8 (9) : 1175-9, "<a href='http://scholar.google.com/scholar?q="Effects+of+Proteolytic+Enzyme+Inhibitors+on+the+Nasal+Absorption+of+Vasoppressin+and+an+Analogue"'>Effects of Proteolytic Enzyme Inhibitors on the Nasal Absorption of Vasoppressin and an Analogue</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">N.R. Anderson, et al., "<a href='http://scholar.google.com/scholar?q="Quantitative+evaluation+of+pharmaceutical+effervescent+systems+II%3A+Stability+monitoring+by+reactivity+and+porosity+measurements"'>Quantitative evaluation of pharmaceutical effervescent systems II: Stability monitoring by reactivity and porosity measurements</a>", Journal of Pharmaceutical Sciences, 71:7-13. (1982).</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nov. 6, 2007 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Observations on European Patent Application No. EP 1251867 (third party observations) dated Jan. 17, 2003.</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Office Action from the European Patent Office concerning European Application Serial No. 01 908 769.1-1219 dated Feb. 2, 2007.</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Okamoto H., et al., J. Pharm. Pharmacol Jul. 1987; 39 (7) : 531-4, "<a href='http://scholar.google.com/scholar?q="Enhanced+penetration+of+mitromycin+C+through+hairless+mouse+and+rats+skin+by+enhancers+with+terpene+moieties"'>Enhanced penetration of mitromycin C through hairless mouse and rats skin by enhancers with terpene moieties</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">56</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opinion and Order dated Aug. 28, 2008, in Unigene Laboratories, Inc., et al. v. Apotex, Inc., et al., 06, CV 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">57</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">P. Graf et al., Clin., Exp. Allergy, vol. 25:395-400; 1995 "<a href='http://scholar.google.com/scholar?q="Benzalkoium+chloride+in+a+decongestant+nasal+spray+aggravates+Rhinitis+medicamentosa+in+healthy+volunteers"'>Benzalkoium chloride in a decongestant nasal spray aggravates Rhinitis medicamentosa in healthy volunteers</a>".</td></tr><tr><td class="patent-data-table-td ">58</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">P. Nykänen, et al., "<a href='http://scholar.google.com/scholar?q="Organic+acids+as+excipients+in+matrix+granules+for+colon-specific+drug+delivery"'>Organic acids as excipients in matrix granules for colon-specific drug delivery</a>", Int. J. Pharm. 184:251-261. (1999).</td></tr><tr><td class="patent-data-table-td ">59</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">P.C. Braga et al., J. Pharm. Pharmacol. 44:938-940; 1992 "<a href='http://scholar.google.com/scholar?q="The+effects+of+calcitonin+nsala+preparations+and+their+excipients+on+mucociliary+clearance+in+an+ex-vivo+frog+palate+test"'>The effects of calcitonin nsala preparations and their excipients on mucociliary clearance in an ex-vivo frog palate test</a>".</td></tr><tr><td class="patent-data-table-td ">60</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Patent family search for EP 0358234 (equiv. USP 5,026,825),1/34/1 Dialog(R) File 351:Derwent abstract, (008189979, "<a href='http://scholar.google.com/scholar?q="Intranasal+calcitonin+formulations-contg.+Delta-amino-laevulinic+acid+for+enhanced+bioavailability"'>Intranasal calcitonin formulations-contg. Delta-amino-laevulinic acid for enhanced bioavailability</a>" (priority application 1988).</td></tr><tr><td class="patent-data-table-td ">61</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Patent family search for GB 2212062 (equiv. EP 0327756), 2/34/1 Dialog(R) File 351: Derwent abstract, 007943804, "<a href='http://scholar.google.com/scholar?q="Pharmaceutical+Calcitonin-contg.+for+nasal+glycyrrihizinate+to+enhance+mucosal+membrane+absorption%2C+esp.+for+nasal+administration"'>Pharmaceutical Calcitonin-contg. for nasal glycyrrihizinate to enhance mucosal membrane absorption, esp. for nasal administration</a>" (priority application 1987).</td></tr><tr><td class="patent-data-table-td ">62</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippincott Williams &amp; Wilkins, pp. 77-81 (1999).</td></tr><tr><td class="patent-data-table-td ">63</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Physicians' Desk Reference 52nd Edition at 1880-1881 (1998).</td></tr><tr><td class="patent-data-table-td ">64</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Physicians' Desk Reference-PDR 53 Edition 1999, pp. 2057-2059.</td></tr><tr><td class="patent-data-table-td ">65</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pillion D.J., et al., J. Pharm. Sci. Nov. 1995; 84 (11) : 1276-9, "<a href='http://scholar.google.com/scholar?q="DS-1%2C+A+Modified+Quillaja+Saponin%2C+Enhances+Ocula+and+Nasal+Absorption+of+Insulin"'>DS-1, A Modified Quillaja Saponin, Enhances Ocula and Nasal Absorption of Insulin</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">66</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Plaintiffs'<a href='http://scholar.google.com/scholar?q="+Memorandum+of+Law+in+Opposition+to+Defendants%27+Motion+for+Reconsideration+of+the+Feb.+4%2C+2008+Order+Regarding+Defendants"'> Memorandum of Law in Opposition to Defendants' Motion for Reconsideration of the Feb. 4, 2008 Order Regarding Defendants</a>' Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP).</td></tr><tr><td class="patent-data-table-td ">67</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pontiroli A.E., et al., Eur J Clin Pharmacol 1989; 37 (4) : 427-30, "<a href='http://scholar.google.com/scholar?q="Nasal+Administration+of+Glucagon+and+Human+Calcitonin+to+Healthy+Subjects%3A+A+Comparison+of+Powders+and+Spray+Solutions+and+of+Different+Enhancing+Agents"'>Nasal Administration of Glucagon and Human Calcitonin to Healthy Subjects: A Comparison of Powders and Spray Solutions and of Different Enhancing Agents</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">68</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">R.C. Henrikson, et al., Histology, Lippincott Williams and Wilkins pp. 311-321 at 314 (1997).</td></tr><tr><td class="patent-data-table-td ">69</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ratafia, Manny, et al. M&amp;M Medical Marketing &amp; Media, vol. 24; No. 11, p. 10; "<a href='http://scholar.google.com/scholar?q="Drug+Delivery%3A+the+Key+to+Biotechnology+Markets"'>Drug Delivery: the Key to Biotechnology Markets</a>", Oct. 1, 1989.</td></tr><tr><td class="patent-data-table-td ">70</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rebuttal Declaration and Expert Report of Ashim K. Mitra, Ph.D.</td></tr><tr><td class="patent-data-table-td ">71</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rebuttal Declaration and Expert Report of Michael Sofocleous.</td></tr><tr><td class="patent-data-table-td ">72</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rebuttal Declaration and Expert Report of Professor Alexander M. Klibanov Regarding Invalidity of U.S. Pat. No. 6,440,392.</td></tr><tr><td class="patent-data-table-td ">73</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rebuttal Declaration and Expert Report of Professor Robert S. Langer Regarding Invalidity of U.S. Pat. No. 6,440,392.</td></tr><tr><td class="patent-data-table-td ">74</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Remington, The Science and Practice of Pharmacy, 20th Edition, Philadelphia (USA) Jan. 2000, Chapter 47, pp. 922-923.</td></tr><tr><td class="patent-data-table-td ">75</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Repertorio Farmaceutico Italiano, REFI 4a Edizione (REFI 4th Edition), 1990, p. A 212, (Calcitonina Spray Nasale Arnmour, and p. A223 "<a href='http://scholar.google.com/scholar?q="Carbicalcin+Spray"'>Carbicalcin Spray</a>", Farmindustria, Associazione dell'Idustria Farmaceutica (National Association of the Pharmaceutical Industry)-CEDOF Editor, 1990.</td></tr><tr><td class="patent-data-table-td ">76</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Reubsaet et al., "<a href='http://scholar.google.com/scholar?q="Degradation+kinetics+of+antagonist+%5BArg6%2C+D-Trp7%2C9%2C+MePhe8%5D-substance+P%7B6-11%7D+in+aqueous+solutions"'>Degradation kinetics of antagonist [Arg6, D-Trp7,9, MePhe8]-substance P{6-11} in aqueous solutions</a>", Analytical Biochemistry 227:334-341. (1995).</td></tr><tr><td class="patent-data-table-td ">77</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Romeijn S.G., et al., Int. J. Pharm.,1996,135/1-2 (137-145), "<a href='http://scholar.google.com/scholar?q="The+Effect+of+Nasal+Drug+Formulations+on+Ciliary+Beating+in+vitro"'>The Effect of Nasal Drug Formulations on Ciliary Beating in vitro</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">78</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Santus G., et al., Farmaco Dec. 1993; 48 (12) : 1709-33, "<a href='http://scholar.google.com/scholar?q="Nasal+Formulations+of+Ketorolac+Tromethamine%3A+Technological+Evaluation-Bioavailability+and+Tolerability+in+Rabbits"'>Nasal Formulations of Ketorolac Tromethamine: Technological Evaluation-Bioavailability and Tolerability in Rabbits</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">79</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sarkar M.A., Pharm Res Jan. 1992; 9 (1) : 1-9, "<a href='http://scholar.google.com/scholar?q="Drug+Metabolism+in+the+Nasal+Mucosa"'>Drug Metabolism in the Nasal Mucosa</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">80</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Schipper N.G., et al., Pharm Res Nov. 1996; 13 (11) : 1686-92, "<a href='http://scholar.google.com/scholar?q="Chitosans+as+Absorption+Enhancers+for+Poorly+Absorbable+Drugs.+1%3A+Influence+of+Molecular+Weight+and+Degree+of+Acetylation+on+Drug+Transport+Across+Human+Intestinal+Epithelial+%28Caco-2%29+Cells"'>Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">81</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Schipper N.G.M., et al., Calcif. Tissue Int.,1995, 56/4 (280-282) "<a href='http://scholar.google.com/scholar?q="Methylated+%28beta%29-cyclodextrins+are+Able+to+Improve+the+Nasal+Absorption+of+Salmon+Calcitonin"'>Methylated (beta)-cyclodextrins are Able to Improve the Nasal Absorption of Salmon Calcitonin</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">82</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Second Declaration of Inventor William Stern Under 37 CFR § 1.132 dated Sep. 7, 2007.</td></tr><tr><td class="patent-data-table-td ">83</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Shao Z., et al., Pharm Res Sep. 1992: 9 (9) : 1157-63, "<a href='http://scholar.google.com/scholar?q="Cyclodextrins+as+Nasal+Absorption+Promoters+of+Insulin+%3A+Mechanistic+Evaluations"'>Cyclodextrins as Nasal Absorption Promoters of Insulin : Mechanistic Evaluations</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">84</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Stephen G. Farmer and Douglas W.P. Hay, Editors, The Airway Epithelium: Physiology, Pathophysiology and Pharmacology 1991: 3-39, Marcel Dekker, Inc.</td></tr><tr><td class="patent-data-table-td ">85</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sugibayashi K., et al., J. Pharm. Pharmacol Aug. 1985; 37 (8) : 578-80, "<a href='http://scholar.google.com/scholar?q="Effect+of+the+Absorption+Enhancer%2C+Azone%2C+on+the+Transport+of+5-Fluorouracil+Across+Hairless+Rat+Skin"'>Effect of the Absorption Enhancer, Azone, on the Transport of 5-Fluorouracil Across Hairless Rat Skin</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">86</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tengamnuay P., et al., Pharm Res Apr. 1990; 7 (4) : 370-5, "<a href='http://scholar.google.com/scholar?q="Bile+Salt-Fatty+Acid+Mixed+Micelles+as+Nasal+Absorption+Promoters+of+Peptides.+II.+In+vivo+Nasal+Absorption+of+Insulin+in+Rats+and+Effects+of+Mixed+Micelles+on+the+Morphological+Integrity+of+the+Nasal+Mucosa"'>Bile Salt-Fatty Acid Mixed Micelles as Nasal Absorption Promoters of Peptides. II. In vivo Nasal Absorption of Insulin in Rats and Effects of Mixed Micelles on the Morphological Integrity of the Nasal Mucosa</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">87</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Merck Index, 13th Edition, 2001, p. 3576.</td></tr><tr><td class="patent-data-table-td ">88</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Third Declaration of inventor William Stern under 37 C.F.R. § 1.132, with Exhibits.</td></tr><tr><td class="patent-data-table-td ">89</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tyler-Cross et al., "<a href='http://scholar.google.com/scholar?q="Effects+of+amino+acids+sequence%2C+buffers%2C+and+ionic+strength+on+the+rate+and+mechanism+of+deamidation+of+asparagine+residues+in+small+peptides"'>Effects of amino acids sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides</a>", Journal of Biological Chemistry 266:22549-22556. (1991).</td></tr><tr><td class="patent-data-table-td ">90</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">V. Agarwal et al., "<a href='http://scholar.google.com/scholar?q="Recent+trends+in+drug+delivery+systems%3A+intranasal+drug+delivery"'>Recent trends in drug delivery systems: intranasal drug delivery</a>", Indian Journal of Experimental Biology, 37:6-16. (1999).</td></tr><tr><td class="patent-data-table-td ">91</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Vermehren C:, et al., Drug Metab Dispos Sep. 1997; 25 (9): 1083-8, "<a href='http://scholar.google.com/scholar?q="Absorption+and+Metabolism+of+the+Absorption+Enhancer+Didecanoylphosphatidylcholine+in+Rabbit+Nasal+Epithelium+in+vivo"'>Absorption and Metabolism of the Absorption Enhancer Didecanoylphosphatidylcholine in Rabbit Nasal Epithelium in vivo</a>", abstract.</td></tr><tr><td class="patent-data-table-td ">92</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wade &amp; Weller, Handbook of Pharmaceutical Excipients, 2nd Edition, American Pharmaceutical Association and the Pharmaceutical Press, pp. 34-37, 122-125, 339-345, 439-440 (1994).</td></tr><tr><td class="patent-data-table-td ">93</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Windisch, V. et al., "<a href='http://scholar.google.com/scholar?q="Degradation+Pathways+of+Salmon+Calcitonin+in+Aqueous+Solution"'>Degradation Pathways of Salmon Calcitonin in Aqueous Solution</a>", J. Pharm. Sci., 86, 359-364. (1997).</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8377863">US8377863</a></td><td class="patent-data-table-td patent-date-value">May 28, 2008</td><td class="patent-data-table-td patent-date-value">Feb 19, 2013</td><td class="patent-data-table-td ">Unigene Laboratories Inc.</td><td class="patent-data-table-td ">Peptide pharmaceutical for oral delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8513183">US8513183</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 2011</td><td class="patent-data-table-td patent-date-value">Aug 20, 2013</td><td class="patent-data-table-td ">Enteris Biopharma, Inc.</td><td class="patent-data-table-td ">Peptide pharmaceutical for oral delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8592366">US8592366</a></td><td class="patent-data-table-td patent-date-value">Jun 4, 2012</td><td class="patent-data-table-td patent-date-value">Nov 26, 2013</td><td class="patent-data-table-td ">Enteris Biopharma, Inc.</td><td class="patent-data-table-td ">Peptide pharmaceutical for oral delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/USRE43580">USRE43580</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 29, 2009</td><td class="patent-data-table-td patent-date-value">Aug 14, 2012</td><td class="patent-data-table-td ">Unigene Laboratories, Inc.</td><td class="patent-data-table-td ">Nasal calcitonin formulations</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S434000">424/434</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S455000">424/455</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S045000">424/45</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S001100">514/1.1</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009120000">A61K9/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009000000">A61K9/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038230000">A61K38/23</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K9/0043">A61K9/0043</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5aPIBQABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/23">A61K38/23</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K9/00M14</span>, <span class="nested-value">A61K38/23</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Nov 12, 2013</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIM 19 IS CONFIRMED; CLAIMS 1-18 AND 20-29 WERE PREVIOUSLY CANCELLED</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 3, 2013</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 1-12, 15, 18 AND 20-23 WERE PREVIOUSLY CANCELLED; CLAIMS 13, 14, 16, 17 AND 24-29 ARE CANCELLED; CLAIM 19 WAS NOT REEXAMINED</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 23, 2013</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20130611</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">UGP THERAPEUTICS, INC., ILLINOIS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIGENE LABORATORIES, INC.;REEL/FRAME:030856/0340</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 5, 2013</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20121220</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 12, 2012</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">UNIGENE LABORATORIES INC., NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20010208</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STERN, WILLIAM;REEL/FRAME:028947/0938</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 6, 2011</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20110715</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 3, 2008</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">VICTORY PARK MANAGEMENT, LLC, ILLINOIS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:UNIGENE LABORATORIES, INC.;REEL/FRAME:021630/0352</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20080930</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_4ff636b3d23669b7103f3b3a3a18b4cd.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U3YaCBhxY7xFc1YYWUI_U2gwK6rZQ\u0026id=5aPIBQABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U2OH-NjMGxIfPecoC4b6AAUoLAiqA\u0026id=5aPIBQABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U0GiTH23HmkhByt8y4vfvgdryszSA","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Liquid_pharmaceutical_composition_for_na.pdf?id=5aPIBQABERAJ\u0026output=pdf\u0026sig=ACfU3U2kOL0LV6_y_KliPQjWJg6roYTOsw"},"sample_url":"http://www.google.com/patents/reader?id=5aPIBQABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>